Investment
Features
FeesSafety
Academy
More
Pluang+

Waystar stock rises 8.6% amid strategic review including possible sale, with $30 price target set.

Market News
15 Sep 2026
Gordon Thompson
View Source
Bullish
Waystar stock rises 8.6% amid strategic review including possible sale, with $30 price target set.

Waystar Holding Corp, a healthcare software company valued at around $5.1 billion, saw its stock rise 8.6% to $27.05 following reports that it is evaluating strategic options, including a potential sale. Barclays set a new price target of $30, suggesting an 11.57% upside despite a recent downgrade. If sold, Waystar could return to private ownership just two years after going public. This strategic review has heightened investor interest and stock volatility.

Waystar Holding Corp's stock activity is presented here as market context. For readers following healthcare software companies, here is Pluang's market snapshot as of Sep 16, 2026 00:52 WIB: Among 91 priced health-sector US stocks tradable on Pluang, 28 rose and 63 fell today. Notable movers include ASND at USD 231.16 with a 1-day change of -12.74%, ILMN at USD 225.13 up 8.13%, and TXG at USD 75.05 up 7.05%.

More News

MasterCraft beats Q4 estimates with $129.94M revenue, boosted by Marine Products acquisition.

MasterCraft beats Q4 estimates with $129.94M revenue, boosted by Marine Products acquisition.

MasterCraft Boat Holdings reported fiscal Q4 2026 adjusted earnings of $0.67 per share and revenue of $129.94 million, surpassing estimates. Revenue growth was driven by its Performance and Wake business and the Marine Products acquisition, which add...

Company Fundamentals
Bullish
19 minutes ago
Redwood Trust CFO buys shares amid calls to sell the company at a 33% book value discount

Redwood Trust CFO buys shares amid calls to sell the company at a 33% book value discount

Redwood Trust's CFO, Carillo Brooke, increased her stake by purchasing 26,065 shares, showing confidence despite a major shareholder urging the board to consider selling the company. The stock trades at a 33% discount to its GAAP book value due to ri...

Market News
Neutral
25 minutes ago
BioMarin's stock target raised to $97 after positive rare disease drug trial and new board appointment

BioMarin's stock target raised to $97 after positive rare disease drug trial and new board appointment

BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth ...

Analyst Insights
Bullish
1 hour ago
Comcast plans major split of its tech and media businesses amid mixed investor reactions

Comcast plans major split of its tech and media businesses amid mixed investor reactions

Comcast announced a strategic restructuring to separate its connectivity and technology division from its media operations, including NBCUniversal and Sky. UBS raised Comcast's price target to $27, suggesting a 10% upside from current prices. The com...

Company Fundamentals
Neutral
3 hours ago
Vera Bradley beats earnings estimates with $0.11 EPS and 1.1% revenue growth, driven by 'Project Sunshine'.

Vera Bradley beats earnings estimates with $0.11 EPS and 1.1% revenue growth, driven by 'Project Sunshine'.

Vera Bradley reported a strong quarter with earnings per share of $0.11, beating analyst expectations of a $0.08 loss. Revenue rose 1.1% year-over-year to $71.65 million, supported by an 8.0% increase in direct-to-consumer sales. The company’s ongoin...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App